RetinalGenix Technologies Inc. Share Price
Equities
RTGN
US76133Y1055
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.5 USD | +12.90% | -.--% | +13.27% |
Sales 2022 | - | Sales 2023 | - | Capitalization | 54.35M 4.54B |
---|---|---|---|---|---|
Net income 2022 | -3M -250M | Net income 2023 | -2M -167M | EV / Sales 2022 | - |
Net Debt 2022 | 0.16 13.2 | Net Debt 2023 | 0.51 42.27 | EV / Sales 2023 | - |
P/E ratio 2022 |
-35.8
x | P/E ratio 2023 |
-25.6
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 29.99% |
1 day | +12.90% | ||
3 months | +12.90% | ||
6 months | +13.27% | ||
Current year | +13.27% |
Managers | Title | Age | Since |
---|---|---|---|
Erhan Gunday
FOU | Founder | - | - |
Jerry Katzman
CEO | Chief Executive Officer | 71 | 01/18/01 |
Director of Finance/CFO | 66 | 30/11 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jerry Katzman
CEO | Chief Executive Officer | 71 | 01/18/01 |
Herbert L. Gould
BRD | Director/Board Member | 95 | 01/19/01 |
Vinay Mehindru
BRD | Director/Board Member | - | 26/22/26 |
1st Jan change | Capi. | |
---|---|---|
+13.27% | 62.25M | |
+22.37% | 46.4B | |
-1.12% | 41.75B | |
+47.70% | 41.37B | |
-3.52% | 29.71B | |
+10.33% | 26.01B | |
-19.72% | 19.52B | |
+30.70% | 12.43B | |
-0.08% | 12.18B | |
-0.02% | 12.13B |
- Stock Market
- Equities
- RTGN Stock